Gufic Biosciences Limited — Q1 FY26 earnings call

Call held 14 Aug 2025

Management summary

Gufic BioScience reported a strong Q1 FY26, driven primarily by the operational ramp-up of its Indore facility, which contributed an additional INR 25-26 crores in revenue. The company saw significant QoQ growth in revenue, EBITDA, PBT, and PAT, alongside margin expansion. Management highlighted strategic shifts in key divisions, expansion of its aesthetic and reproductive medicine portfolios, and a clear roadmap for international growth, while also addressing near-term challenges related to working capital and cash flow.

Highlights

  • Total revenue from operations for Q1 FY26 was INR 226.9 crores, up 10.68% QoQ from INR 205 crores in Q4 FY25.

  • EBITDA for Q1 FY26 stood at INR 33.2 crores, a 22.96% QoQ increase from INR 27 crores in Q4 FY25.

  • EBITDA margin improved to 14.63% in Q1 FY26 from 13.17% in Q4 FY25.

  • Profit Before Tax (PBT) for Q1 FY26 was INR 16.3 crores, a 50.92% QoQ increase from INR 10.8 crores in Q4 FY25.

  • Profit After Tax (PAT) for Q1 FY26 was INR 12.1 crores, a 51.25% QoQ increase from INR 8 crores in Q4 FY25.

  • The Indore facility contributed significantly to the revenue increase, with capacity utilization at 18-20% in Q1 FY26, targeting 30% by Q3 FY26.

  • The Sparsh division's annual revenue is around INR 55-56 crores, with a target to reach INR 100 crores in 2-3 years.

  • Export revenue is expected to be around 20-22% of total revenue this year, with Q1 FY26 exports at INR 53 crores.

Key financials

  1. Revenue ₹226.9 Cr +10.7%QoQ
  2. EBITDA ₹33.2 Cr +23%QoQ
  3. EBITDA Margin 14.6%
  4. PBT ₹16.3 Cr +50.9%QoQ
  5. PAT ₹12.1 Cr +51.2%QoQ
  6. PAT Margin 5.3%

What they filed

Q1 FY27: revenue up 15.0%, net profit up 83.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue204 208 205 227 230 +13%231 +11%252 +23%261 +15%
EBITDA39 34 27 32 36 −8%36 +6%46 +70%47 +47%
Net profit22 19 8 12 15 −32%16 −16%21 +163%22 +83%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Domestic Sales
    50% Revenue Share
  • Export Sales
    20% Revenue Share₹53 Cr Q1 FY26 Revenue
  • CMO Sales
    25% Revenue Share
  • API Sales
    5% Revenue Share
  • Sparsh Division
    ₹55 Cr Annual Revenue
  • Critical Care (Specific Product/Sub-segment)
    ₹20 Cr Annual Revenue
  • Puregraf (Annual Run Rate)
    ₹25 Cr Revenue
  • Guficin Alpha (Annual Run Rate)
    ₹10 Cr Revenue

Guidance & targets

Capacity

  • Indore Capacity Utilization Capacity · FY26 · High confidence 30%
    We reached 30% capacity utilization in FY '26, which is the current year

    — Avik Das

  • Indore Lyophilization Capacity Utilization (Q1) Capacity · Q1 FY26 · High confidence 18-20%
    we already are on around 18% to 20% in Q1. So we foresee that and I'm talking, of course, about the lyophilization capacity.

    — Pranav Choksi

  • Indore Lyophilization Capacity Utilization (Mid-year) Capacity · October or November · High confidence 25%
    Liquid and ampule, we hope that by somewhere by around October or November, we should be close to 25%.

    — Pranav Choksi

  • Indore Lyophilization Capacity Utilization (Q3) Capacity · Q3 FY26 · High confidence 30%
    by the third quarter of this financial year, we should be around 30% and maybe beyond also.

    — Pranav Choksi

Profitability

  • Indore EBITDA Profitability · FY26 · High confidence Breakeven
    breakeven on EBITDA for Indore in the same year

    — Avik Das

  • Indore Asset Contribution Profitability · From FY27 onwards · High confidence Margin-accretive
    positioned Indore as a margin-accretive asset from FY '27 onwards.

    — Avik Das

  • EBITDA Breakeven (Indore) Profitability · This year · High confidence Achieved
    we have a prediction that we should be breaking even in EBITDA this year.

    — Pranav Choksi

  • Interest and Depreciation Recovery (Indore) Profitability · Once 35% utilization reached · High confidence Achieved
    if we reach the capacity utilization around 35%, that moment of time, we will be able to recover the interest and depreciation cost also.

    — Devkinandan Roonghta

  • EBITDA Margin Profitability · FY27-28 onwards · Medium confidence Improvement
    Then '27-'28, we will expect the margin will improve. But definitely, after increasing the export as well as export has been touched to 25%, there will be increasing in the EBITDA margin by 1%. So I feel that EBITDA margin will going to come only after 2 years, not from not '26-'27 and '27-'28. '28-'29 onwards, I will see that the EBITDA margin will start picking up.

    — Devkinandan Roonghta

Revenue

  • Sparsh Annual Revenue Revenue · Next 2-3 years · Medium confidence INR 100 crores
    Internal targets would be close to INR100.

    — Pranav Choksi

  • FY26 Total Revenue Revenue · FY26 · Low confidence INR 1,000 crores
    I would love to put a number on it. But yes, our efforts are fully on to reach that magical figure as soon as possible.

    — Pranav Choksi

  • Export Revenue Share Revenue · This year · High confidence 20-22%
    I think according to me, the export would be around 20%, 20 to 22% of increasing this year.

    — Pranav Choksi

Debt

  • Debt Status Debt · By 2029 · Medium confidence Debt-free
    I think the company will become debt-free by 2029.

    — Devkinandan Roonghta

Market Share

  • Stunnox Market Share Market Share · Long-term · Medium confidence 30-40%

    From 12% today

    increase the market share to at least 30%, 40% and create a good, I would say, equity here in India first and then take it abroad.

    — Pranav Choksi

  • International Market Share (8 molecules) Market Share · Next 3-5 years · Medium confidence 5-10%
    We are targeting a 3- to 5-year horizon to capture 5% to 10% market share across these high-potential molecules in the identified market

    — Avik Das

Market context

  • Global Regulatory Audit (EU/UK MHRA) Regulatory · Q1 FY27 · Medium confidence Received
    One of the key milestones will be the global regulatory audit, which we hope to receive from the EU side -- EU and UK MHRA side by Q1 of FY '27.

    — Avik Das

Risks & concerns

  • Working Capital Pressure

    medium

    Additional working capital required for the Indore plant scale-up and increased payment cycles post-COVID (120 days vs 90 days pre-COVID) will put pressure on working capital for the current year.

    Management acknowledged

  • Cash Flow Strain

    medium

    Cash flow will be under pressure for FY25-26 due to the additional working capital needs of the Indore facility, with no surplus cash expected until after FY27.

    Management acknowledged

  • EBITDA Margin Pressure

    medium

    EBITDA margin is expected to face pressure in FY26-27 before improving in FY27-28 and picking up significantly from FY28-29 onwards.

    Management acknowledged

  • Regulatory Delays for Exports

    medium

    FDA permissions from the US and Europe, along with validation batches, are time-consuming, making it difficult to anticipate exact expected turnover from exports.

    Management acknowledged

Areas of evasion (2)

  • Exact volume growth percentage for the quarter
  • Specific revenue potential/timeline for new licensing deals

Q&A highlights

2 direct
Indore plant revenue contribution and Critical Care price erosion Direct
whatever increase you see around close to INR25 crores to INR26 crores is mostly at the benefit of Indore. ... So in Critical Care, the price erosion has stopped. There is no further price erosion happening in Critical Care as of now.

Clarified the immediate financial impact of the new Indore facility and confirmed stabilization of pricing in a key segment.

Asked by Bhavya Sonawala

EBITDA to cash flow conversion and Sparsh project impact Partial
the hospitals in India, unfortunately, have a habit of paying almost after 120, 150 or sometimes even 180 days. ... we would be maybe going back in the next 3 to 6 months back to the CNF model where we again get the what you call the distributors in place where at least our collection and our, I would say, outstanding, which is currently around 120 to 150 days in that division comes back to that 45-day average.

Revealed a significant operational challenge (stretched payment cycles in Sparsh) impacting cash flow and outlined a potential strategic shift to address it.

Asked by Kumar Saurabh

Overall revenue growth and segment performance Direct
the numbers which have evolved from, I think, INR690 crores, INR800 crores, INR800 crores and then whatever comes this year, we -- especially last, INR690 crores to INR800 crores was one jump and then INR800 became flat at INR800 because of 2 reasons as I mentioned last time. One was, of course, erosion of prices, which was to the tune of INR120 crores to but more importantly, that capacity was the biggest concern which we faced.

Provided historical context for revenue stagnation, attributing it to price erosion and capacity constraints, and explained how the Indore plant is now addressing these issues for future growth.

Asked by Nitya Shah

3 min read 6 chapters

Detailed narrative

Q1 FY26 Financial Performance Overview

Gufic BioScience reported a robust Q1 FY26, with total revenue from operations reaching INR 226.9 crores, marking a 10.68% sequential growth from INR 205 crores in Q4 FY25. This growth was largely attributed to the initial contributions from the new Indore facility. The company also demonstrated strong profitability improvements, with EBITDA increasing by 22.96% QoQ to INR 33.2 crores, and EBITDA margin expanding to 14.63% from 13.17%. PBT and PAT also saw significant QoQ increases of 50.92% and 51.25% respectively, reaching INR 16.3 crores and INR 12.1 crores.

Indore Facility Ramp-up and Strategic Role

The Indore facility is progressing well, having completed 15 vendor audits and secured 145 state FDA approvals. Capacity utilization for lyophilized injectables reached 18-20% in Q1 FY26, with targets to hit 25% by October/November and 30% by Q3 FY26. Management expects the Indore plant to achieve EBITDA breakeven in FY26 and become a margin-accretive asset from FY27. This facility is crucial for tech transfers from Navsari, freeing up capacity for exports, and is designed to meet global regulatory standards, with EU/UK MHRA audits anticipated by Q1 FY27.

Strategic Shifts in Critical Care and Sparsh Divisions

The Critical Care division is focusing on scientific engagement and therapy leadership, refreshing its anti-infective portfolio with differentiated combinations. The Sparsh division is undergoing a strategic shift under new leadership, aiming for deeper hospital penetration and a broader high-science offering. While Sparsh currently generates INR 55-56 crores annually, the company targets to grow this to INR 100 crores in the next 2-3 years. Management is re-evaluating Sparsh's direct-to-hospital distribution model due to extended payment cycles (120-180 days), considering a return to a CNF model to improve cash flow.

Aesthetic and Reproductive Medicine Portfolio Expansion

In the toxin segment (Aesthaderm), Gufic is broadening its portfolio beyond botulinum toxin to include fillers, skin boosters, and biostimulators, with in-licensing discussions underway for a top filler biosimulator brand. Stunnox continues its growth momentum, holding the number two position in India, with a long-term goal to increase its market share to 30-40% from the current 12%. The Ferticare cluster is also strengthening its scientific positioning and selectively introducing differentiated therapies, including the recent launch of an immune therapy for recurrent implantation failure.

International Business and Export Growth

Gufic is actively pursuing international expansion, targeting a 5-10% market share in an $824 million addressable market for eight key molecules over the next 3-5 years. Export revenue constituted INR 53 crores in Q1 FY26, representing approximately 20-22% of total revenue. The Navsari Unit 2, which is EU GMP-approved, is currently servicing the UK NHS tender award. The Indore facility is expected to further boost export capabilities, with exports to Southeast Asia and Africa anticipated by December 2025 or early next year, and EU exports by Q1 FY27.

Working Capital and Debt Management

The company acknowledged that working capital will be under pressure for FY25-26 due to the scaling up of the Indore plant and an increase in average payment cycles post-COVID (from 90 to 120 days). Cash flow is expected to remain strained until after FY27. However, management has a clear plan for debt reduction, aiming to become debt-free by 2029. EBITDA margins are projected to face pressure in FY26-27 but are expected to improve from FY27-28 onwards, with a 1% increase anticipated once export share reaches 25%.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls